Literature DB >> 17235682

Safety and efficacy of catheter ablation of atrial fibrillation in patients with diabetes mellitus--single center experience.

Ri Bo Tang1, Jian Zeng Dong, Xing Peng Liu, Dong Ping Fang, De Yong Long, Xiao Hui Liu, Rong Hui Yu, Fu Li Hu, Chun Shan Lu, Peng Hao, Jérôme Kalifa, Chang Sheng Ma.   

Abstract

BACKGROUND AND
OBJECTIVE: Little is known about the outcome of catheter ablation of atrial fibrillation (AF) in patients with diabetes mellitus (DM). We investigated the safety and efficacy of catheter ablation of AF in patients with DM.
MATERIALS AND METHODS: Thirty one patients with DM from a group of 263 consecutive patients undergoing a first-time catheter ablation of AF procedure were enrolled in a prospective study. The ablation protocol (guided by CARTO system) consisted in two continuous circular lesions around ipsilateral pulmonary veins.
RESULTS: The following clinical characteristics differed between DM and no-DM patients: age (62.0 +/- 10.8 vs. 56.1 +/- 10.6 years, P = 0.004), longer AF history (9.6 +/- 9.3 vs. 6.7 +/- 6.3 years, P = 0.024), significantly larger left atrium size (41.1 +/- 7.8 vs. 38.3 +/- 5.8 mm, P = 0.021), hypertension (58.1 vs. 35.8%, P = 0.018) and structural heart disease (67.7 vs. 43.5%, P = 0.011). Despite a similar AF recurrence rate in DM and no-DM patients (32.3 vs. 22.4%, P = 0.240), the ablation procedure was complicated in 28 patients (11 hematomas, three cardiac tamponades and three strokes) and the incidence of complications was significantly higher in DM than in no-DM patients (29.0 vs. 8.2%, respectively, P = 0.002). Multivariate analysis showed that DM was an independent risk factor for complications occurrence (odd ratio 5.936, 95% confidence interval 2.059 to 17.112, P = 0.001).
CONCLUSIONS: First catheter ablation of AF procedure in DM patients was equally efficacious than in no-DM patients. However, DM patients had a higher incidence of complications, mostly thrombotic or hemorrhagic.

Entities:  

Mesh:

Year:  2007        PMID: 17235682     DOI: 10.1007/s10840-006-9049-x

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  32 in total

1.  Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.

Authors:  Hitinder S Gurm; Ian J Sarembock; Dean J Kereiakes; John J Young; Robert A Harrington; Neal Kleiman; Frederick Feit; Kathy Wolski; John A Bittl; Robert Wilcox; Eric J Topol; A Michael Lincoff
Journal:  J Am Coll Cardiol       Date:  2005-06-21       Impact factor: 24.094

2.  [Effect of the metabolic syndrome on the electrophysiological parameters of the heart].

Authors:  N N Kipshidze; G A Katsitadze; L B Khosroshvili
Journal:  Georgian Med News       Date:  2005-02

3.  Interpretation of relevance of sodium-calcium exchange in action potential of diabetic rat heart by mathematical model.

Authors:  Nazmi Yaras; Belma Turan
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

4.  Modulation of potassium currents by angiotensin and oxidative stress in cardiac cells from the diabetic rat.

Authors:  Y Shimoni; D Hunt; M Chuang; K Y Chen; G Kargacin; D L Severson
Journal:  J Physiol       Date:  2005-06-09       Impact factor: 5.182

5.  Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.

Authors:  Abhiram Prasad; Gregg W Stone; Thomas D Stuckey; Costantino O Costantini; Peter J Zimetbaum; Michael McLaughlin; Roxana Mehran; Eulogio Garcia; James E Tcheng; David A Cox; Cindy L Grines; Alexandra J Lansky; Bernard J Gersh
Journal:  J Am Coll Cardiol       Date:  2005-02-15       Impact factor: 24.094

6.  Incidence of and risk factors for atrial fibrillation in older adults.

Authors:  B M Psaty; T A Manolio; L H Kuller; R A Kronmal; M Cushman; L P Fried; R White; C D Furberg; P M Rautaharju
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

7.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

8.  Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study.

Authors:  Carlo Pappone; Salvatore Rosanio; Giuseppe Augello; Giuseppe Gallus; Gabriele Vicedomini; Patrizio Mazzone; Simone Gulletta; Filippo Gugliotta; Alessia Pappone; Vincenzo Santinelli; Valter Tortoriello; Simone Sala; Alberto Zangrillo; Giuseppe Crescenzi; Stefano Benussi; Ottavio Alfieri
Journal:  J Am Coll Cardiol       Date:  2003-07-16       Impact factor: 24.094

9.  Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community.

Authors:  C J Ostgren; J Merlo; L Råstam; U Lindblad
Journal:  Diabetes Obes Metab       Date:  2004-09       Impact factor: 6.577

Review 10.  [Diabetes in Japan and the global burden of diabetes].

Authors:  Yoshiharu Akazawa; Shunichi Akazawa
Journal:  Nihon Rinsho       Date:  2002-08
View more
  8 in total

Review 1.  The Impact of Advances in Atrial Fibrillation Ablation Devices on the Incidence and Prevention of Complications.

Authors:  Fehmi Keçe; Katja Zeppenfeld; Serge A Trines
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-08

Review 2.  Diabetes, Obesity and Atrial Fibrillation: Epidemiology, Mechanisms and Interventions.

Authors:  O Asghar; U Alam; S A Hayat; R Aghamohammadzadeh; A M Heagerty; R A Malik
Journal:  J Atr Fibrillation       Date:  2013-08-31

3.  QTc interval predicts outcome of catheter ablation in paroxysmal atrial fibrillation patients with type 2 diabetes mellitus.

Authors:  Ning Ma; Xiao-Yan Wu; Chang-Sheng Ma; Nian Liu; Rong Bai; Xin Du; Yan-Fei Ruan; Jian-Zeng Dong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

Review 4.  Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation.

Authors:  Jonathan Nyong; Guy Amit; Alma J Adler; Onikepe O Owolabi; Pablo Perel; David Prieto-Merino; Pier Lambiase; Juan Pablo Casas; Carlos A Morillo
Journal:  Cochrane Database Syst Rev       Date:  2016-11-22

Review 5.  Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes.

Authors:  Laurel A Grisanti
Journal:  Front Physiol       Date:  2018-11-26       Impact factor: 4.566

Review 6.  Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions.

Authors:  O Asghar; U Alam; S A Hayat; R Aghamohammadzadeh; A M Heagerty; R A Malik
Journal:  Curr Cardiol Rev       Date:  2012-11

Review 7.  Mechanism of and therapeutic strategy for atrial fibrillation associated with diabetes mellitus.

Authors:  Yubi Lin; Hairui Li; Xianwu Lan; Xianghui Chen; Aidong Zhang; Zicheng Li
Journal:  ScientificWorldJournal       Date:  2013-03-14

8.  Catheter ablation of atrial fibrillation in patients with diabetes mellitus.

Authors:  Allen Wang; Tracy Truong; Eric Black-Maier; Cynthia Green; Kristen B Campbell; Adam S Barnett; Janice Febre; Zak Loring; Sana M Al-Khatib; Brett D Atwater; James P Daubert; Camille Frazier-Mills; Donald D Hegland; Kevin P Jackson; Larry R Jackson; Jason I Koontz; Robert K Lewis; Sean D Pokorney; Albert Y Sun; Kevin L Thomas; Tristam D Bahnson; Jonathan P Piccini
Journal:  Heart Rhythm O2       Date:  2020-05-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.